IFN-λ: A new class of interferon with distinct functions-implications for hepatitis c virus research

Gastroenterology Research and Practice

Volumn 2015, Issue , 2015, Pages

  Liu, Bing ^a   McGilvray, Ian ^a,b   Chen, Limin ^a,b  

^a INSTITUTE OF BLOOD TRANSFUSION   (China)

^b UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BOCEPREVIR; GAMMA 1 INTERFERON; GAMMA 1A INTERFERON; GAMMA 2 INTERFERON; GAMMA 3 INTERFERON; GAMMA 4 INTERFERON; GAMMA INTERFERON; GAMMA INTERFERON RECEPTOR; HOST FACTOR; INTERLEUKIN 28B; PEGINTERFERON ALPHA; RECOMBINANT ALPHA INTERFERON; RECOMBINANT GAMMA 1 INTERFERON; RECOMBINANT GAMMA INTERFERON; RIBAVIRIN; SOFOSBUVIR; TELAPREVIR; UNCLASSIFIED DRUG;

CHRONIC HEPATITIS C; DRUG TREATMENT FAILURE; GENE MUTATION; GENETIC VARIABILITY; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; PROTEIN FUNCTION; PROTEIN LOCALIZATION; REVIEW; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT OUTCOME; TREATMENT RESPONSE; VIRUS LOAD;

EID: 84930621945     PISSN: 16876121     EISSN: 1687630X     Source Type: Journal    
DOI: 10.1155/2015/796461     Document Type: Review

References (86)

1. M. F. Sorrell, E. A. Belongia, J. Costa et al., "National Institutes of Health consensus development conference statement: management of hepatitis B," Hepatology, vol. 49, no. 5, pp. S4-S12, 2009.
2. J. J. Feld, "The beginning of the end: what is the future of interferon therapy for chronic hepatitis C?" Antiviral Research, vol. 105, pp. 32-38, 2014.
3. P. Sheppard,W. Kindsvogel,W. Xu et al., "IL-28, IL-29 and their class II cytokine receptor IL-28R," Nature Immunology, vol. 4, no. 1, pp. 63-68, 2003.
4. S. V. Kotenko, G. Gallagher, V. V. Baurin et al., "IFN-λs mediate antiviral protection through a distinct class II cytokine receptor complex," Nature Immunology, vol. 4, no. 1, pp. 69-77, 2003.
5. L. Prokunina-Olsson, B. Muchmore, W. Tang et al., "A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus," Nature Genetics, vol. 45, no. 2, pp. 164-171, 2013.
6. T. R. O'Brien, L. Prokunina-Olsson, and R. P. Donnelly, "IFN-λ4: the paradoxical new member of the interferon lambda family," Journal of Interferon & Cytokine Research, vol. 34, no. 11, pp. 829-838, 2014.
7. C. Kelly, P. Klenerman, and E. Barnes, "Interferon lambdas: the next cytokine storm," Gut, vol. 60, no. 9, pp. 1284-1293, 2011.
8. K. Witte, G. Gruetz,H.-D. Volk et al., "Despite IFN-λ receptor expression, blood immune cells, but not keratinocytes or melanocytes, have an impaired response to type III interferons: Implications for therapeutic applications of these cytokines," Genes & Immunity, vol. 10, no. 8, pp. 702-714, 2009.
9. C. Sommereyns, S. Paul, P. Staeheli et al., "IFN-Lambda (IFN-λ) is expressed in a tissue-dependent fashion and primarily acts on epithelial cells in vivo," PLoS Pathogens, vol. 4, no. 3, Article ID e1000017, 2008.
10. A.Meager,K.Visvalingam, P.Dilger,D. Bryan, andM.Wadhwa, "Biological activity of interleukins-28 and-29: comparison with type I interferons," Cytokine, vol. 31, no. 2, pp. 109-118, 2005.
11. N. E. Pagliaccetti andM.D.Robek, "Interferon-λ in theimmune response to hepatitis B virus and hepatitis C virus," Journal of Interferon&Cytokine Research, vol. 30, no. 8, pp. 585-590, 2010.
12. K. Wolk, K. Witte, E. Witte et al., "Maturing dendritic cells are an important source of IL-29 and IL-20 that may cooperatively increase the innate immunity of keratinocytes," Journal of Leukocyte Biology, vol. 83, no. 5, pp. 1181-1193, 2008.
13. S. Marukian, L. Andrus, T. P. Sheahan et al., "Hepatitis C virus induces interferon-λ and interferon-stimulated genes in primary liver cultures," Hepatology, vol. 54, no. 6, pp. 1913-1923, 2011.
14. F. J. D. Mennechet and G. Uzé, "Interferon-λ-treated dendritic cells specifically induce proliferation of FOXP3-expressing suppressor T cells," Blood, vol. 107, no. 11, pp. 4417-4423, 2006.
15. S. E. Doyle, H. Schreckhise, K. Khuu-Duong et al., "Interleukin-29 uses a type 1 interferon-like program to promote antiviral responses in human hepatocytes," Hepatology, vol. 44, no. 4, pp. 896-906, 2006.
16. K. Onoguchi, M. Yoneyama, A. Takemura et al., "Viral infections activate types I and III interferon genes through a common mechanism,"The Journal of Biological Chemistry, vol. 282, no. 10, pp. 7576-7581, 2007.
17. Z.Makowska andM.H.Heim, "Interferon signaling in the liver during hepatitis C virus infection," Cytokine, vol. 59, no. 3, pp. 460-466, 2012.
18. P. I. Österlund, T. E. Pietilä, V. Veckman, S. V. Kotenko, and I. Julkunen, "IFN regulatory factor family members differentially regulate the expression of type III IFN (IFN-λ) genes," The Journal of Immunology, vol. 179, no. 6, pp. 3434-3442, 2007.
19. S. M. Horner and M. Gale Jr., "Regulation of hepatic innate immunity by hepatitis C virus," Nature Medicine, vol. 19, no. 7, pp. 879-888, 2013.
20. J.Wu and Z. J. Chen, "Innate immune sensing and signaling of cytosolic nucleic acids," Annual Review of Immunology, vol. 32, no. 1, pp. 461-488, 2014.
21. M. H. Heim, "Innate immunity and HCV," Journal of Hepatology, vol. 58, no. 3, pp. 564-574, 2013.
22. N. Jilg, W. Lin, J. Hong et al., "Kinetic differences in the induction of interferon stimulated genes by interferon-λ and interleukin 28B are altered by infection with hepatitis C virus," Hepatology, vol. 59, no. 4, pp. 1250-1261, 2014.
23. R.-X. Shao, L. Zhang, Z. Hong et al., "SOCS1 abrogates IFN's antiviral effect on hepatitis C virus replication," Antiviral Research, vol. 97, no. 2, pp. 101-107, 2013.
24. V. François-Newton, G. M. de Freitas Almeida, B. Payelle-Brogard et al., "USP18-based negative feedback control is induced by type I and type III interferons and specifically inactivates interferon λ response," PLoS ONE, vol. 6, no. 7, Article ID e22200, 2011.
25. C. Koh and T. J. Liang, "What is the future of ribavirin therapy for hepatitis C?" Antiviral Research, vol. 104, no. 1, pp. 34-39, 2014.
26. M. Sarasin-Filipowicz, "Interferon therapy of hepatitis C: molecular insights into success and failure," Swiss Medical Weekly, vol. 140, no. 1-2, pp. 3-11, 2010.
27. J. J.Feldand J.H.Hoofnagle, "Mechanismof actionof interferon and ribavirin in treatment of hepatitis C," Nature, vol. 436, no. 7053, pp. 967-972, 2005.
28. F. Lin and H. A. Young, "Interferons: success in anti-viral immunotherapy,"Cytokine&Growth Factor Reviews, vol. 25,no. 4, pp. 369-376, 2014.
29. K. E. Sherman, S. L. Flamm, N. H. Afdhal et al., "Responseguided telaprevir combination treatment for hepatitis C virus infection," The New England Journal of Medicine, vol. 365, no. 11, pp. 1014-1024, 2011.
30. S. Zeuzem, P. Andreone, S. Pol et al., "Telaprevir for retreatment of HCV infection," The New England Journal of Medicine, vol. 364, no. 25, pp. 2417-2428, 2011.
31. J. Jaroszewicz, R. Flisiak, and G. Dusheiko, "A pill for HCV-myth or foreseeable future?" Liver International, vol. 34, no. 1, pp. 6-11, 2014.
32. Z. Zhou, O. J. Hamming, N. Ank, S. R. Paludan, A. L. Nielsen, and R. Hartmann, "Type III interferon (IFN) induces a type I IFN-like response in a restricted subset of cells through signaling pathways involving both the Jak-STAT pathway and the mitogen-activated protein kinases," Journal of Virology, vol. 81, no. 14, pp. 7749-7758, 2007.
33. J. Pott, T. Mahlakõiv, M. Mordstein et al., "IFN-λ determines the intestinal epithelial antiviral host defense," Proceedings of the NationalAcademy of Sciences of theUnited States ofAmerica, vol. 108, no. 19, pp. 7944-7949, 2011.
34. M. Sarasin-Filipowicz, X.Wang,M. Yan et al., "Alpha interferon induces long-lasting refractoriness of JAK-STAT signaling in themouse liver through induction ofUSP18/UBP43,"Molecular and Cellular Biology, vol. 29, no. 17, pp. 4841-4851, 2009.
35. H. Qashqari, A. Al-Mars, A. Chaudhary et al., "Understanding the molecular mechanism(s) of hepatitis C virus (HCV) induced interferon resistance," Infection,Genetics and Evolution, vol. 19, pp. 113-119, 2013.
36. Z. Makowska, F. H. T. Duong, G. Trincucci, D. F. Tough, and M. H. Heim, "Interferon-λ and interferon-λ signaling is not affected by interferon-induced refractoriness to interferon-λ in vivo," Hepatology, vol. 53, no. 4, pp. 1171-1180, 2011.
37. B. Edlich, G. Ahlenstiel, A. A. Zabaleta et al., "Early changes in interferon signaling define natural killer cell response and refractoriness to interferon-based therapy of hepatitis C patients," Hepatology, vol. 55, no. 1, pp. 39-48, 2012.
38. Z. Yin, J. Dai, J. Deng et al., "Type III IFNs are produced by and stimulate human plasmacytoid dendritic cells," The Journal of Immunology, vol. 189, no. 6, pp. 2735-2745, 2012.
39. D. Olagnier and J. Hiscott, "Type I and type III interferoninduced immune response: it's a matter of kinetics and magnitude," Hepatology, vol. 59, no. 4, pp. 1225-1228, 2014.
40. E. L. Ramos, "Preclinical and clinical development of pegylated interferon-lambda 1 in chronic hepatitis C," Journal of Interferon and Cytokine Research, vol. 30, no. 8, pp. 591-595, 2010.
41. A. J. Muir, M. L. Shiffman, A. Zaman et al., "Phase 1b study of pegylated interferon lambda 1 with or without ribavirin in patients with chronic genotype 1 hepatitis C virus infection," Hepatology, vol. 52, no. 3, pp. 822-832, 2010.
42. X. Wang, M. Hruska, P. Chan et al., "Derivation of Phase 3 dosing for peginterferon lambda-1a in chronic hepatitis C, Part 1: modeling optimal treatment duration and sustained virologic response rates," The Journal of Clinical Pharmacology, vol. 55, no. 1, pp. 63-72, 2015.
43. M. Hruska, X. Wang, P. Chan et al., "Derivation of Phase 3 dosing for peginterferon lambda-1a in chronic hepatitis C, Part 2: exposure-response analyses for efficacy and safety variables," The Journal of Clinical Pharmacology, vol. 55, no. 1, pp. 73-80, 2015.
44. D. Ge, J. Fellay, A. J. Thompson et al., "Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance," Nature, vol. 461, no. 7262, pp. 399-401, 2009.
45. I.McGilvray, J. J. Feld, L. Chen et al., "Hepatic cell-type specific gene expression better predicts HCV treatment outcome than IL28B genotype," Gastroenterology, vol. 142, no. 5, pp. 1122.e1-1131.e1, 2012.
46. B. I. Chen L, J. Sun, M. Guindi et al., "Cell-type specific gene expression signature in liver underlies response to interferon therapy in chronic hepatitis C infection," Gastroenterology, vol. 138, no. 3, pp. 1123-1133, 2010.
47. P. V. Aka, M. H. Kuniholm, R. M. Pfeiffer et al., "Association of the IFNL4-G allele with impaired spontaneous clearance of hepatitis C virus," Journal of Infectious Diseases, vol. 209, no. 3, pp. 350-354, 2014.
48. Y.Nagaoki, M. Imamura,Y.Kawakami et al., "Interferon lambda 4 polymorphism affects on outcome of telaprevir, pegylated interferon and ribavirin combination therapy for chronic hepatitis C," Hepatology Research, vol. 44, no. 14, pp. E447-E454, 2014.
49. P. Simmonds, J. Bukh, C. Combet et al., "Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes," Hepatology, vol. 42, no. 4, pp. 962-973, 2005.
50. B. L. Pearlman and N. Traub, "Sustained virologic response to antiviral therapy for chronic hepatitis C virus infection: a cure and so much more," Clinical Infectious Diseases, vol. 52, no. 7, pp. 889-900, 2011.
51. M. G. Ghany, D. B. Strader, D. L. Thomas, and L. B. Seeff, "Diagnosis, management, and treatment of hepatitis C: an update," Hepatology, vol. 49, no. 4, pp. 1335-1374, 2009.
52. M. W. Fried, M. L. Shiffman, K. R. Reddy et al., "Peginterferon alfa-2a plus ribavirin for chronic hepatitisCvirus infection,"The New England Journal of Medicine, vol. 347, no. 13, pp. 975-982, 2002.
53. C. Sarrazin, C. Hézode, S. Zeuzem, and J.-M. Pawlotsky, "Antiviral strategies in hepatitis C virus infection," Journal of Hepatology, vol. 56, supplement 1, pp. S88-S100, 2012.
54. P. Halfon, A. U. Neumann, M. Bourlière et al., "Slow viral dynamics of hepatitis C virus genotype 4," Journal of Viral Hepatitis, vol. 10, no. 5, pp. 351-353, 2003.
55. H. Toyoda, T. Kumada, N. Shimada et al., "Baseline factors and early viral response (week 4) to antiviral therapy with peginterferon and ribavirin for predicting sustained virologic response in patients infected with hepatitis C virus genotype 1: a multicenter study," Journal of Medical Virology, vol. 85, no. 1, pp. 65-70, 2013.
56. M. W. Fried, S. J. Hadziyannis, M. L. Shiffman, D. Messinger, and S. Zeuzem, "Rapid virological response is the most important predictor of sustained virological response across genotypes in patients with chronic hepatitis C virus infection," Journal of Hepatology, vol. 55, no. 1, pp. 69-75, 2011.
57. Y. Wada, H. Tamai, A. Uno et al., "Prediction of efficacy to pegylated interferon-λ-2b plus ribavirin in patients with genotype 2 hepatitis C virus using viral response within 2 weeks," Hepatology Research, vol. 44, no. 2, pp. 179-186, 2014.
58. J. Itakura, Y. Asahina, N. Tamaki et al., "Changes in hepatitis C viral load during first 14 days can predict the undetectable time point of serum viral load by pegylated interferon and ribavirin therapy," Hepatology Research, vol. 41, no. 3, pp. 217-224, 2011.
59. O. Stambouli, Hepatitis C Virus:Molecular Pathways and Treatments, 2014.
60. N. Enomoto, I. Sakuma, Y. Asahina et al., "Comparison of fulllength sequences of interferon-sensitive and resistant hepatitis C virus 1b: sensitivity to interferon is conferred by amino acid substitutions in the NS5A region," The Journal of Clinical Investigation, vol. 96, no. 1, pp. 224-230, 1995.
61. K. Hayashi, Y. Katano, M. Ishigami et al., "Mutations in the core and NS5A region of hepatitis C virus genotype 1b and correlation with response to pegylated-interferon-alpha 2b and ribavirin combination therapy," Journal of Viral Hepatitis, vol. 18, no. 4, pp. 280-286, 2011.
62. P. M. de Rueda, J. Casado, R. Patón et al., "Mutations in E2-PePHD, NS5A-PKRBD, NS5A-ISDR, and NS5A-V3 of hepatitis C virus genotype 1 and their relationships to pegylated interferon-ribavirin treatment responses," Journal of Virology, vol. 82, no. 13, pp. 6644-6653, 2008.
63. S. Kitamura, M. Tsuge, T. Hatakeyama et al., "Amino acid substitutions in core and NS5A regions of the HCV genome can predict virological decrease with pegylated interferon plus ribavirin therapy," AntiviralTherapy, vol. 15,no. 8, pp. 1087-1097, 2010.
64. R. Kozuka, M. Enomoto, H. Hai et al., "Changes in sequences of core region, interferon sensitivity-determining region and interferon and ribavirin resistance-determining region of hepatitis C virus genotype 1 during interferon-alpha and ribavirin therapy, and efficacy of retreatment," Hepatology Research, vol. 42, no. 12, pp. 1157-1167, 2012.
65. S. Sakamoto, J. Qin, A. Navarro et al., "Cells previously desensitized to type 1 interferons display different mechanisms of activation of stat-dependent gene expression from naïve cells," The Journal of Biological Chemistry, vol. 279, no. 5, pp. 3245-3253, 2004.
66. G. C. MacQuillan, W. B. de Boer, M. A. Platten et al., "Intrahepatic MxA and PKR protein expression in chronic hepatitis C virus infection," Journal ofMedical Virology, vol. 68, no. 2, pp. 197-205, 2002.
67. T. Asselah, I. Bieche, S. Narguet et al., "Liver gene expression signature to predict response to pegylated interferon plus ribavirin combination therapy in patientswith chronic hepatitis C," Gut, vol. 57, no. 4, pp. 516-523, 2008.
68. J. Hou, G. van Oord, Z. M. A. Groothuismink et al., "Gene expression profiling to predict and assess the consequences of therapy-induced virus eradication in chronic hepatitis C virus infection," Journal of Virology, vol. 88, no. 21, pp. 12254-12264, 2014.
69. L. Chen, I. Borozan, J. Feld et al., "Hepatic gene expression discriminates responders and nonresponders in treatment of chronic hepatitis C viral infection," Gastroenterology, vol. 128, no. 5, pp. 1437-1444, 2005.
70. Y. Zhu, B. Qin, C. Xiao, X. Lu, and L. Chen, "Cell-type specific interferon stimulated gene staining in liver underlies response to interferon therapy in chronic hbv infected patients," Digestive Diseases and Sciences, vol. 57, no. 9, pp. 2355-2361, 2012.
71. G. Randall, L. Chen, M. Panis et al., "Silencing of USP18 potentiates the antiviral activity of interferon against hepatitis C virus infection," Gastroenterology, vol. 131, no. 5, pp. 1584-1591, 2006.
72. M. Sarasin-Filipowicz, E. J.Oakeley, F. H. T. Duong et al., "Interferon signaling and treatment outcome in chronic hepatitis C," Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 19, pp. 7034-7039, 2008.
73. T. Huang, K. Tu, Y. Shyr, C.-C. Wei, L. Xie, and Y.-X. Li, "The prediction of interferon treatment effects based on time series microarray gene expression profiles," Journal of Translational Medicine, vol. 6, no. 1, article 44, 2008.
74. N. I. Rallon, L. A. Lopez-Fernandez, M. I. Garcia et al., "Interferon-stimulated genes are associated with peginterferon/ ribavirin treatment response regardless of IL28B alleles in hepatitis C virus/HIV-coinfected patients," AIDS, vol. 27, no. 5, pp. 687-696, 2013.
75. E. G.Meissner, D. Bon, L. Prokunina-Olsson et al., "IFNL4-δG genotype is associated with slower viral clearance in Hepatitis C, genotype-1 patients treated with sofosbuvir and ribavirin," Journal of Infectious Diseases, vol. 209, no. 11, pp. 1700-1704, 2014.
76. V. Suppiah, M. Moldovan, G. Ahlenstiel et al., "IL28B is associated with response to chronic hepatitisCinterferon-λ and ribavirin therapy," Nature Genetics, vol. 41, no. 10, pp. 1100-1104, 2009.
77. Y. Tanaka, N. Nishida, M. Sugiyama et al., "Genome-wide association of IL28B with response to pegylated interferon-λ and ribavirin therapy for chronic hepatitis C," Nature Genetics, vol. 41, no. 10, pp. 1105-1109, 2009.
78. H. Ochi, T. Maekawa, H. Abe et al., "Il-28b predicts response to chronic hepatitis C therapy-fine-mapping and replication study in Asian populations," Journal of General Virology, vol. 92, no. 5, pp. 1071-1081, 2011.
79. K. Ray, "Hepatitis: new gene IFNL4 is associated with impaired clearance of HCV," Nature Reviews Gastroenterology and Hepatology, vol. 10, no. 2, p. 63, 2013.
80. O. J. Hamming, E. Terczyńska-Dyla, G. Vieyres et al., "Interferon lambda 4 signals via the IFNλ receptor to regulate antiviral activity against HCV and coronaviruses," The EMBO Journal, vol. 32, no. 23, pp. 3055-3065, 2013.
81. L. M. Real, K. Neukam, R. Herrero et al., "IFNL4 ss469415590 variant shows similar performance to rs12979860 as predictor of response to treatment against hepatitis C virus genotype 1 or 4 in Caucasians," PLoS ONE, vol. 9, no. 4,Article ID e95515, 2014.
82. H. Konishi, T. Motomura, Y. Matsumoto et al., "Interferonlambda4 genetic polymorphism is associated with the therapy response for hepatitis C virus recurrence after a living donor liver transplant," Journal of ViralHepatitis, vol. 21,no. 6, pp. 397-404, 2014.
83. S. Zeuzem, V. Soriano, T. Asselah et al., "Faldaprevir and deleobuvir for HCV genotype 1 infection," The New England Journal of Medicine, vol. 369, no. 7, pp. 630-639, 2013.
84. S. Franco, E. Aparicio,M. Parera, B. Clotet, C. Tural, andM. A. Martinez, "IFNL4 ss469415590 variant is a better predictor than rs12979860 of pegylated interferon-alpha/ribavirin therapy failure in hepatitis C virus/HIV-1 coinfected patients," AIDS, vol. 28, no. 1, pp. 133-136, 2014.
85. L. Covolo, S. Bibert, F. Donato et al., "The novel ss469415590 variant predicts virological response to therapy in patients with chronic hepatitis C virus type 1 infection," Alimentary Pharmacology &Therapeutics, vol. 39, no. 3, pp. 322-330, 2014.
86. S. Akkarathamrongsin, V. D. Thong, S. Payungporn et al., "IFNL3 (IL28B) and IFNL4 polymorphisms are associated with treatment response in Thai patients infected with HCV genotype 1, but not with genotypes 3 and 6," Journal of Medical Virology, vol. 86, no. 9, pp. 1482-1490, 2014.